← All trials
NCT03837925
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 13, 2019
- Primary completion
- Oct 1, 2021
- Completion date
- Oct 1, 2021
- First posted
- —
- Last posted
- —
- Enrollment
- 130
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- French Cardiology SocietyLead sponsor
- New Mexico State UniversityCollaborator
- Fondation Coeur et RechercheCollaborator
- Fédération francaise de cardiologieCollaborator
- Sorbonne UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.